177-Lu labeled peptide for site-specific uPAR-targeting
US10994032B2 · kind B2 · utility
2Cited by
14References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 3, 2013 |
| Grant date | May 4, 2021 |
| Priority date | — |
| Expiry date | May 8, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/6456
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.